Aimmune To Host Conference Call On Potential Positive Implications For AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness In Young Peanut-Allergic Children

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that management will host a conference call to highlight the results of an independent academic clinical trial demonstrating the ability of low-dose oral immunotherapy to induce sustained unresponsiveness in peanut-allergic children under three years of age.